<DOC>
	<DOCNO>NCT02902744</DOCNO>
	<brief_summary>Primary Objective : • To collect post-approval safety data related intraocular pressure ( IOP ) one injection Iluvien standard care subject diabetic macular edema ( DME ) . Secondary Objectives : • To collect visual anatomic outcome data one injection Iluvien standard care subject diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Fluocinolone Acetonide Insert ( ILUVIEN® ) Diabetic Macular Edema ( FAD ) Study</brief_title>
	<detailed_description>Diabetic retinopathy ( DR ) major complication diabetes mellitus lead significant visual morbidity . Important feature DR microaneurysms , vascular leakage , vascular occlusion , retinal neovascularization . Diabetic macular edema ( DME ) occur leakage macula , central region retina responsible fine visual acuity . DME prevalent cause moderate visual loss patient diabetes . ( 1 ) Treatment option DME include use focal/grid laser photocoagulation ( 2 ) , intravitreal anti-VEGF therapy ( 3-5 ) , intravitreal steroid therapy ( 6 ) steroid implant insertion vitreous cavity ( 7-9 ) . Corticosteroids known beneficial treatment DME reduce expression vascular endothelial growth factor ( VEGF ) inflammatory cytokine e.g . Interleukin-6 , play major role pathogenesis DME . ( 10 ) . Iluvien® ( Alimera Sciences , Inc. , Alpharetta , GA ) low dose , sustain release corticosteroid insert recently FDA approve use patient DME . ( 10 , 11 ) Structurally nonbiodegradable , cylindrical polymer tube measure 3.5x0.37 mm release 0.19 µg/day Fluocinolone Acetonide . These insert inject vitreous cavity outpatient set 25-gauge injector system use MedidurTM ( Alimera Sciences , Inc. ) technology find beneficial compare sham treatment 3 year . ( 10 , 11 ) As complication steroid implant sometimes result dose dependent elevation intraocular pressure ( IOP ) increase risk glaucoma susceptible patient . The purpose study look post-approval safety data relate IOP one injection Iluvien standard care subject DME . Objectives Primary Objective : • To collect post-approval safety data related intraocular pressure ( IOP ) one injection Iluvien standard care subject diabetic macular edema ( DME ) . Secondary Objectives : • To collect visual anatomic outcome data one injection Iluvien standard care subject diabetic macular edema ( DME ) . Study Procedures This study assess long term safety , visual , anatomic outcome subject receive 1 injection Iluvien standard care DME . Fifty patient clinic population Wilmer Eye Institute enrol study duration 60 month . Subjects measurement BCVA , IOP eye exam baseline month 12 , 24 , 36 , 48 , 60 . All follow treatment clinic patient 's treating physician . Data clinic note collect case report form adverse event document .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Subjects receive Iluvien standard care DME Understands procedures requirement study provide write informed consent authorization protect health information disclosure . • None</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>